Drugs and Engineer - Clinical Research Informer

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. The post Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run appeared first on Pharmaceutical Technology.

Engineer

Engineer Vaccine Vaccination Clinical Trials

With $100M AstraZeneca deal, a biotech and its investors engineer another buyout

Bio Pharma Dive

JULY 5, 2022

An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.

Engineer

Engineer Antibody Drugs

Google-backed Isomorphic Labs raises $600m to advance AI drug discovery

Pharmaceutical Technology

MARCH 31, 2025

The funding is set to accelerate the development of Isomorphics AI drug design engine and advance clinical programmes.

Engineer

Engineer Drugs Development

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Engineers design sutures that can deliver drugs or sense inflammation

Medical Xpress

MAY 16, 2023

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

Engineer

Engineer Drugs Development

Synlogic’s SYNB1934 receives orphan drug status from US FDA

Pharmaceutical Technology

MAY 10, 2023

Synlogic has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for SYNB1934 to treat phenylketonuria (PKU), a rare inherited metabolic disease. The orally administered, non-systemically absorbed drug candidate SYNB1934 has been designed for reducing blood phenylalanine (Phe) levels in PKU patients.

Genetic Engineering

Genetic Engineering Drugs Engineer Genetics

Atomwise and Sanofi partner for drug discovery using AI

Pharmaceutical Technology

AUGUST 18, 2022

Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally. The post Atomwise and Sanofi partner for drug discovery using AI appeared first on Pharmaceutical Technology.

Drugs

Drugs Engineer Medicine Sales

Researchers develop CRISPR-based drug candidate for microbiome targeting

Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The team then engineered the phages through gene editing to improve their targeting ability.

Development

Development Bacteria Research Drugs

Genesis raises $200m for AI drug discovery engine

pharmaphorum

AUGUST 21, 2023

Genesis raises $200m for AI drug discovery engine Phil.Taylor Mon, 21/08/2023 - 20:10 Bookmark this

Engineer

Engineer Drugs

BioMed X and Sanofi partner to leverage AI for drug development

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Development

Development Drugs In-Vivo Engineer

Do generics producers have what it takes to tackle complex and specialty drugs?

Pharmaceutical Technology

JULY 25, 2022

Specialty generics is a term used to refer to generic versions of drugs that are often expensive, complex, or “high touch”—requiring significant involvement of service to manage. Specialty drugs are most used to treat different cancers, rheumatoid arthritis, and multiple sclerosis. The only way forward for generics producers.

Drugs

Drugs Manufacturing Production Marketing

Editas grabs orphan drug status for sickle cell disease CRISPR therapy

Pharmaceutical Technology

APRIL 28, 2023

The US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to Editas Medicine’s gene therapy EDIT-301 in sickle cell disease, based on an April 27 announcement. The US agency previously granted the Orphan Drug Designation to EDIT-301 for its study in beta thalassemia, in May 2022.

Gene Therapy

Gene Therapy Drugs Gene Gene Editing

Alkermes separates cancer drug business as new company Mural

Bio Pharma Dive

NOVEMBER 15, 2023

Now independent Mural Oncology will focus on advancing a pipeline of engineered cytokines for cancer, while Alkermes has recast itself as a “pure-play” neuroscience company.

Engineer

Engineer Drugs

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

JUNE 29, 2022

The pharmaceutical industry often relies on enzymes to perform a process known as biocatalysis, which facilitates the cost-effective and sustainable production of small molecule drugs at scale. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior.

Drugs

Drugs Gene Therapy Production Manufacturing

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here. CIGB is headquartered in Cuba.

Genetic Engineering

Genetic Engineering Engineer Genetics Clinical Trials

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here. CIGB is headquartered in Cuba.

Genetic Engineering

Genetic Engineering Engineer Genetics Clinical Trials

Ono and EVQLV partner to develop new antibody drugs

Pharmaceutical Technology

DECEMBER 22, 2023

Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.

Antibody

Antibody Development Engineer Drugs

Artificial Intelligence innovation: Leading companies in in-silico drug discovery

Pharmaceutical Technology

FEBRUARY 23, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Artificial Intelligence in Pharmaceuticals: In-silico drug discovery. Codexis, a protein engineering company, is the leading patent filer.

Drugs

Drugs DNA In-Vivo In-Vitro

Why Google Patents Is Not a Good Solution to Identify Drug Patents

Drug Patent Watch

JANUARY 15, 2025

Identifying drug patents is crucial for various stakeholders, including researchers, legal professionals, and business strategists. While Google Patents is a widely used tool for searching patent information, it may not be the most effective solution for identifying drug patents. Challenges in Using Google Patents for Drug Patents 1.

Drugs

Drugs Scientist Engineer Research

AbbVie partners with Immunome for new cancer drug targets discovery

Pharmaceutical Technology

JANUARY 9, 2023

The multi-year collaboration will use Immunome’s Discovery Engine to discover up to ten new antibody pairs arising from three specified types of tumours. We look forward to utilising their Discovery Engine to enhance our existing oncology pipeline.”.

Engineer

Engineer Antibody Drugs Immune Response

Exscientia and Sanofi collaborate to develop AI-driven precision-engineered medicines

Pharma Times

JANUARY 7, 2022

The platform integrates primary human tissue samples into early target and drug discovery research.

Engineer

Engineer Medicine Development Drugs

Scientists engineer brain parasite as novel drug delivery system

BioPharma Reporter

AUGUST 21, 2024

A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.

Drug Delivery Systems

Drug Delivery Systems Drug Delivery Scientist Engineer

Embracing digitalization in the pharmaceutical supply chain

Pharmaceutical Technology

JULY 25, 2022

According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem. Digital technologies will be utilized throughout drug development, production, packaging and delivery for increased process efficiency and improved product quality.

Engineer

Engineer Packaging Packaging Production

US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410

Pharmaceutical Technology

APRIL 26, 2023

The US Food and Drug Administration (FDA) has granted orphan drug designation to IN8bio’s INB-400 and INB-410 to treat a range of malignant gliomas, including newly diagnosed glioblastoma multiforme (GBM). This marks the first-ever designation for genetically modified gamma-delta T cell therapies.

Genetic Engineering

Genetic Engineering Drugs Genetics Engineer

Proxygen and Merck partner to develop molecular glue degraders

Pharmaceutical Technology

APRIL 5, 2023

“This partnership provides us with the framework and resources to further leverage our platform for the discovery of new drugs against challenging targets.” The company has developed a discovery engine that supports the identification of molecular glue degraders against difficult-to-drug or completely undruggable targets.

Development

Development Engineer Sales Research

Health Canada gives approval to Enhertu for breast cancer treatment

Pharmaceutical Technology

JANUARY 13, 2023

Being co-developed and co-marketed by Daiichi Sankyo along with AstraZeneca , Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC).

HR

HR Trials Engineer Clinical Trials

New lupus partnership with FDA aims to end drug trials’ history of failure

STAT News

MARCH 29, 2023

And hopeful patients, many of them young women of color, are waiting — just three lupus drugs have been approved by the Food and Drug Administration in six decades. Together, they created what lupus advocates hope will be an engine for innovation: the Lupus Accelerating Breakthroughs Consortium, or Lupus ABC.

Drug Trials

Drug Trials Trials Drugs Engineer

Scientists discover non-invasive approach for cancer therapy

Pharmaceutical Technology

APRIL 11, 2023

The finding was made as part of a study published in the journal Nature Biomedical Engineering. Kelley added: “Engineering-based tools allow you to do things that open up new areas of biology. CTRL Therapeutics will file an application with the US Food and Drug Administration (FDA) to advance the new platform into clinical trials.

Scientist

Scientist Engineer Clinical Trials Clinical Trials

Capsida Biotherapeutics and Prevail to develop CNS gene therapies

Pharmaceutical Technology

JANUARY 5, 2023

Under the multi-year strategic partnership, Prevail will detect and advance capsids, which are clinically translatable, along with its cargo to develop the transformative genetic medicines by using Capsida’s novel adeno-associated virus (AAV) engineering platform.

Gene Therapy

Gene Therapy Gene Development Engineer

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

XTalks

JANUARY 7, 2025

In a major leap forward for trauma care, Humacyte has received full approval from the US Food and Drug Administration (FDA) for Symvess, a first-of-its-kind bioengineered human tissue designed to repair extremity arterial injuries.

FDA Approval

FDA Approval Engineer Clinical Trials Clinical Trials

Nona and Dragonfly enter HCAb-based drug discovery partnership

Pharmaceutical Technology

NOVEMBER 21, 2022

Nona Biosciences and Dragonfly Therapeutics have signed a partnership agreement to discover and develop heavy chain only antibody (HCAb)-based drugs. These antibodies possess IgG-like PK characteristics and Fc-domain works without requiring further engineering or humanisation.

Antibody

Antibody Drugs Engineer Sales

AI drug discovery firm Valence joins Parkinson’s disease push

pharmaphorum

MARCH 11, 2021

Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkinson’s disease. . The post AI drug discovery firm Valence joins Parkinson’s disease push appeared first on.

Drugs

Drugs Pharmacy Engineer Research

Innovent Biologics files patent for patent filed for novel heterodimeric fc scaffold proteins

Pharmaceutical Technology

MARCH 26, 2024

Discover Innovent Biologics' groundbreaking patent for novel proteins with heterodimeric antibody Fc, revolutionizing antibody engineering and drug development.

Protein

Protein Engineer Antibody Development

US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer

Pharmaceutical Technology

AUGUST 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults. According to the interim efficacy data from a pre-specified patient cohort, a 5.4 In the trial, 1.9%

FDA Approval

FDA Approval Clinical Trials Clinical Trials Engineer

EC approves Briumvi to treat relapsing forms of multiple sclerosis

Pharmaceutical Technology

JUNE 2, 2023

It has been engineered to remove certain sugar molecules generally expressed on the antibody. Last December, the US Food and Drug Administration (FDA) also granted approval to Briumvi to treat RMS in adult patients. The therapy targets a unique epitope on CD20-expressing B-cells.

Antibody

Antibody Engineer Clinical Trials Clinical Trials

Novavax’s Covid-19 vaccine gets Taiwan FDA EUA for use in adults

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

Vaccine

Vaccine Vaccination Clinical Trials Clinical Trials

Develop and execute a winning drug launch strategy with an experienced contract packager

Pharmaceutical Technology

JUNE 14, 2023

A GlobalData report which analyzes trends in new drug approvals [i] shows that small molecule approvals have now been surpassed (in 2022) by biologics. Biologics form 51% of the current global drugs pipeline (highest stage of development as pipeline) according to GlobalData’s Drugs database (as of February 7, 2023).

Contract Packaging

Contract Packaging Packaging Packaging Development

Astellas and Sutro partner to develop immunostimulatory ADCs

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development

Development Antibody Immune Response Production

UNH team finds repurposed drug hinders enzyme activity linked to Covid-19

Pharmaceutical Technology

JUNE 23, 2022

Researchers at the University of New Hampshire (UNH) have found that a repurposed drug, CCG-50014, could hinder the activity of a key enzyme of the SARS-CoV-2 virus, which causes Covid-19. Utilising a currently available drug compound in a new way is called drug repurposing.

Drugs

Drugs Protein Genomics Genome

Telstar promotes 360º solutions at CPhI Worldwide-2021

Pharma Mirror

OCTOBER 29, 2021

Telstar will be actively participating at CPhI, to be held in Milan, during 9-11th November 2021, promoting its personalized GMP consultancy & engineering reply to the new trends in pharma. The post Telstar promotes 360º solutions at CPhI Worldwide-2021 appeared first on Pharma Mirror Magazine.

Engineer

Engineer Compliance Manufacturing Production

Alphabet's Isomorphic raises $600m for AI drug discovery

pharmaphorum

MARCH 31, 2025

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine and advance its pipeline.

Engineer

Engineer Drugs

SPECTRALIS Flex Module Add-On Gets FDA Clearance, Aims to Improve Access to Ophthalmic Imaging

XTalks

OCTOBER 17, 2024

The US Food and Drug Administration (FDA) has granted clearance to imaging and healthcare IT company Heidelberg Engineering’s Flex Module, a multimodal, diagnostic imaging-only platform designed for imaging the posterior segment of pediatric and adult patients in a supine (face up) position.

Engineer

Engineer FDA Approval Marketing Drugs

PCI Pharma Services Invests Over $365 Million in EU, US Facilities to Drive Clinical and Commercial Supply of Advanced Drug Delivery and Drug Device Combination Products

XTalks

JANUARY 29, 2025

Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drug delivery and drug-device combination product assembly in Rockford, Illinois.

Drug Delivery

Drug Delivery Production Packaging Packaging

EU approves Daiichi Sankyo-AstraZeneca’s breast cancer therapy

Pharmaceutical Technology

JANUARY 27, 2023

Being co-developed and co-marketed by AstraZeneca and Daiichi Sankyo, Enhertu is a particularly engineered HER2-directed antibody-drug conjugate (ADC). It has been developed using the DXd ADC technology from Daiichi Sankyo.

HR

HR Engineer Antibody Development

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

SEPTEMBER 16, 2022

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. Verily’s Immune Profiler platform is “a discovery engine consisting of proprietary immune profiling lab workflow, growing multi-omic database, and advanced analytical tools”.

Development

Development Research Drugs Clinical Trials

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

With $100M AstraZeneca deal, a biotech and its investors engineer another buyout

Webinars

Trending Sources

Google-backed Isomorphic Labs raises $600m to advance AI drug discovery

Webinars

Engineers design sutures that can deliver drugs or sense inflammation

Synlogic’s SYNB1934 receives orphan drug status from US FDA

Atomwise and Sanofi partner for drug discovery using AI

Researchers develop CRISPR-based drug candidate for microbiome targeting

Genesis raises $200m for AI drug discovery engine

BioMed X and Sanofi partner to leverage AI for drug development

Do generics producers have what it takes to tackle complex and specialty drugs?

Editas grabs orphan drug status for sickle cell disease CRISPR therapy

Alkermes separates cancer drug business as new company Mural

Enabling the next wave of innovative drug therapies with speciality enzymes

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Ono and EVQLV partner to develop new antibody drugs

Artificial Intelligence innovation: Leading companies in in-silico drug discovery

Why Google Patents Is Not a Good Solution to Identify Drug Patents

AbbVie partners with Immunome for new cancer drug targets discovery

Exscientia and Sanofi collaborate to develop AI-driven precision-engineered medicines

Scientists engineer brain parasite as novel drug delivery system

Embracing digitalization in the pharmaceutical supply chain

US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410

Proxygen and Merck partner to develop molecular glue degraders

Health Canada gives approval to Enhertu for breast cancer treatment

New lupus partnership with FDA aims to end drug trials’ history of failure

Scientists discover non-invasive approach for cancer therapy

Capsida Biotherapeutics and Prevail to develop CNS gene therapies

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

Nona and Dragonfly enter HCAb-based drug discovery partnership

AI drug discovery firm Valence joins Parkinson’s disease push

Innovent Biologics files patent for patent filed for novel heterodimeric fc scaffold proteins

US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer

EC approves Briumvi to treat relapsing forms of multiple sclerosis

Novavax’s Covid-19 vaccine gets Taiwan FDA EUA for use in adults

Develop and execute a winning drug launch strategy with an experienced contract packager

Astellas and Sutro partner to develop immunostimulatory ADCs

UNH team finds repurposed drug hinders enzyme activity linked to Covid-19

Telstar promotes 360º solutions at CPhI Worldwide-2021

Alphabet's Isomorphic raises $600m for AI drug discovery

SPECTRALIS Flex Module Add-On Gets FDA Clearance, Aims to Improve Access to Ophthalmic Imaging

PCI Pharma Services Invests Over $365 Million in EU, US Facilities to Drive Clinical and Commercial Supply of Advanced Drug Delivery and Drug Device Combination Products

EU approves Daiichi Sankyo-AstraZeneca’s breast cancer therapy

The future of AI drug discovery & development in immunology and GPCR research

Stay Connected